Faculty Opinions recommendation of Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

2014 ◽  
Author(s):  
Jean-Pascal Machiels
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Survival Data ◽  
Randomised Trial ◽  
Advanced Head ◽  
Phase 3

Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution.

1991 ◽  
Vol 9 (8) ◽  
pp. 1376-1384 ◽  
Author(s):  
E E Vokes ◽  
R Mick ◽  
E P Lester ◽  
W R Panje ◽  
R R Weichselbaum
Keyword(s):  
Head And Neck Cancer ◽  
Adjuvant Chemotherapy ◽  
Head And Neck ◽  
Induction Chemotherapy ◽  
Neck Cancer ◽  
Survival Data ◽  
Locally Advanced ◽  
Local Therapy ◽  
Complete Response ◽  
Advanced Head

Fifty-one patients with locally advanced head and neck cancer were treated with three cycles of cisplatin at 100 mg/m2 followed by 5-day continuous infusion fluorouracil (5-FU) at 1,000 mg/m2/d as induction chemotherapy. Subsequent local therapy consisted of surgery for patients with resectable disease and/or radiotherapy. Three cycles of adjuvant chemotherapy were administered to patients with partial response (PR) or complete response (CR) to induction chemotherapy. Twenty-two patients (43%) had a clinical CR that was pathologically confirmed in 12 patients (24%), and 24 patients (47%) had a PR for an overall response rate of 90%. Local therapy included surgery in 24 patients (47%) and radiotherapy alone in 22 patients (43%). Adjuvant chemotherapy was administered to 32 patients (63%) frequently at great dose reduction. At a median follow-up of 90 months, the median survival is 22 months (95% confidence interval, 15 to 36 months), and the 5-year survival is 25%, with only five patients known to be alive and disease-free at this time. The median time to progression is 14 months, with 29 patients (57%) having documented progression of their head and neck cancer and eight (16%) having progression of a second neoplasm. Seven patients died of intervening medical events. This high incidence of second malignancies supports the continued investigation of chemoprevention for patients in CR. Despite the known high response rates achieved with cisplatin and 5-FU induction chemotherapy, the overall poor survival data reported here should lead to a thorough reexamination of the frequent administration of this regimen in the community.

scholarly journals A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer

Cancer ◽  
2019 ◽  
Vol 125 (18) ◽  
pp. 3184-3197 ◽  
Author(s):  
Vijay Maruti Patil ◽  
Vanita Noronha ◽  
Amit Joshi ◽  
Jaiprakash Agarwal ◽  
Sarbani Ghosh‐Laskar ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Phase 3

scholarly journals Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial

Cancer ◽  
2010 ◽  
pp. NA-NA ◽  
Author(s):  
Coen R. N. Rasch ◽  
Michael Hauptmann ◽  
Jan Schornagel ◽  
Oda Wijers ◽  
Jan Buter ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Advanced Head ◽  
Phase 3

Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial

2003 ◽  
Vol 67 (1) ◽  
pp. 17-26 ◽  
Author(s):  
Cai Grau ◽  
Jai Prakash Agarwal ◽  
Kaukab Jabeen ◽  
Abdul Rab Khan ◽  
Sarath Abeyakoon ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Mitomycin C ◽  
Neck Cancer ◽  
Randomised Trial ◽  
Locally Advanced ◽  
Advanced Head

scholarly journals Erratum: Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial

Cancer ◽  
2010 ◽  
Vol 116 (15) ◽  
pp. 3750-3750 ◽  
Author(s):  
CRN Rasch ◽  
M Hauptmann ◽  
J Schornagel ◽  
O Wijers ◽  
J Buter ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Advanced Head ◽  
Phase 3
Sign in / Sign up

Export Citation Format

Share Document